Vitamin D Deficiency
Conditions
Keywords
Vitamin D Deficiency, plama osteocalcin, omega-3 fatty acids
Brief summary
Assessing the combined effect of omega-3 fatty acid and vitamin D 3 on plasma osteocalcin levels
Detailed description
The data about effect of vitamin D3 (VD3) and omega-3 fatty acids(omega-3FA) on plasma levels of osteocalcin (OCN) are scarce and conflicting and nothing is published in the literature about the effect of the combination of VD3 and omega-3FA on the OCN levels. This study was conducted to investigate effect of VD3 and omega-3FA alone and with each other on PLASMA OCN levels in females and males with vitamin D deficiency (VDD). This randomized, controlled clinical trial was designed to test effects of 50,000 IU VD3 weekly and 300 mg omega-3FA daily for eight weeks,separately and with each other, on the plasma levels of OCN and 25-hydroxy vitamin D (25OHD). This study was conducted during winter in 86 healthy Jordanian females and males with VDD with a mean age of (40± 10) years. Fasting serum levels for 25OHD,OCN, PTH (parathyroid hormone),calcium, phosphate, ALT (alanine aminotransferase), and urea were assessed at baseline and the end of the trial .
Interventions
DIETARY_SUPPLEMENTvitamin D3
50,000 IU VD3 / week for 8 weeks
DIETARY_SUPPLEMENTomega-3 fatty acid
300 mg of omega 3-FA once daily for 8 weeks
DIETARY_SUPPLEMENTvitamin D3 and omega-3 fatty acid
50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
OTHERcontrol
no intervention
Sponsors
Applied Science Private University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
22 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Medical diagnosis of vitamin D deficiency (VD \< 30 ng / ml).
Exclusion criteria
* People who previously diagnosed with any chronic disease such as kidney diseases were excluded from the study due to the effect of prolonged administration of VD3 on kidney stones formation. * People with bone disorders also excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| vitamin d3 levels | 8 weeks | Plasma levels of 25-hydroxyvitamin D |
| osteocalcin levels | 8 weeks | plasma osteocalcin levels |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PTH | 8 weeks | Plasma concentrations of PTH |
| calcium | 8 weeks | plasma Ca levels |
Countries
Jordan
Outcome results
None listed